5-aminonicotinic-acid and Inflammatory-Bowel-Diseases

5-aminonicotinic-acid has been researched along with Inflammatory-Bowel-Diseases* in 1 studies

Other Studies

1 other study(ies) available for 5-aminonicotinic-acid and Inflammatory-Bowel-Diseases

Article	Year
5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity. Molecular pharmaceutics, 2020, 01-06, Volume: 17, Issue:1 To develop a 5-aminosalicylic acid (5-ASA)-based anticolitic drug with enhanced therapeutic activity, a colon-targeted codrug constituting 5-ASA and a GPR109A agonist was designed. 5-ASA azo-coupled with nicotinic acid (ASA-azo-NA) was synthesized, and the colon specificity and anticolitic effects were evaluated. Approximately 89% of ASA-azo-NA was converted to 5-aminonicotinic acid (5-ANA) and 5-ASA after 24 h of incubation in the cecal contents. 5-ANA was identified as a GPR109A agonist (concentration that gives half-maximal response (EC Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Chromatography, Liquid; Colitis; Colon; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Interleukin-10; Male; Mesalamine; Mice; NF-kappa B; Nicotinic Acids; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Sulfasalazine	2020

Article

Year

5-Aminosalicylic Acid Azo-Coupled with a GPR109A Agonist Is a Colon-Targeted Anticolitic Codrug with a Reduced Risk of Skin Toxicity.

Molecular pharmaceutics, 2020, 01-06, Volume: 17, Issue:1

To develop a 5-aminosalicylic acid (5-ASA)-based anticolitic drug with enhanced therapeutic activity, a colon-targeted codrug constituting 5-ASA and a GPR109A agonist was designed. 5-ASA azo-coupled with nicotinic acid (ASA-azo-NA) was synthesized, and the colon specificity and anticolitic effects were evaluated. Approximately 89% of ASA-azo-NA was converted to 5-aminonicotinic acid (5-ANA) and 5-ASA after 24 h of incubation in the cecal contents. 5-ANA was identified as a GPR109A agonist (concentration that gives half-maximal response (EC

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line, Tumor; Chromatography, Liquid; Colitis; Colon; Drug Delivery Systems; Humans; Inflammatory Bowel Diseases; Interleukin-10; Male; Mesalamine; Mice; NF-kappa B; Nicotinic Acids; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Sulfasalazine

2020